A Study of AZD6738 and Acalabrutinib in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Study identifier:ACE-CL-110

ClinicalTrials.gov identifier:NCT03328273

EudraCT identifier:2016-003737-15

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1 Proof-of-Concept Study Investigating AZD6738 monotherapy and Acalabrutinib in Combination with AZD6738 (ATR inhibitor) in Subjects with Relapsed or Refractory High-risk Chronic Lymphocytic Leukemia (CLL)

Medical condition

Chronic Lymphocytic Leukemia

Phase

Phase 1

Healthy volunteers

No

Study drug

Ceralasertib, Acalabrutinib

Sex

All

Actual Enrollment

11

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 31 Jan 2018
Primary Completion Date: 07 Sept 2021
Estimated Study Completion Date: 26 Aug 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

-

Inclusion and exclusion criteria